Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia by Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid, Aaron D. Schimmer

Get full text